AbbVie Advances Multiple Late-Stage Assets as INTREPID and ABBV‑466 Show Positive Clinical Milestones

This week, AbbVie reported meaningful progress on two clinical fronts: successful topline results from the Phase 3 INTREPID trial of lutikizumab in hidradenitis suppurativa and an investigational dual‑targeting therapy ABBV‑466 showing improved endoscopic remission in moderate to severe Crohn’s disease.

INTREPID Trial Meets Primary Endpoint

On October 22, 2026, AbbVie announced that lutikizumab—its investigational therapy for hidradenitis suppurativa—met the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 in the Phase 3 INTREPID study, compared with placebo. The topline announcement underscores the treatment’s potential to address a significant inflammatory skin condition with limited existing therapies. The report originated directly from the company’s news center. 

ABBV‑466 Shows Promise in Crohn’s Treatment

Two days later, on October 24, 2026, AbbVie provided a data update indicating that its investigational agent ABBV‑466—designed as a dual-targeting therapy against IL‑23 p19 and integrin α4β7—demonstrated higher rates of endoscopic remission at Week 12 relative to monotherapies in patients suffering from moderate to severe Crohn’s disease. This important clinical milestone was disclosed through a regulatory update. 

Market Context

These developments arrive as AbbVie prepares to release its third-quarter earnings on October 30, 2026. While clinical news typically bolsters investor sentiment, there is no confirmed market reaction tied specifically to these announcements. However, over recent weeks, AbbVie’s stock has benefited from its positioning as a defensive growth story amid broader sector gains. Over the past three months, AbbVie stock has risen approximately 12%, outperforming expectations tied to regulatory and political headwinds. 

Furthermore, AbbVie’s assets—including Skyrizi and Rinvoq—continue to drive core performance, while pipeline progress like the INTREPID and ABBV‑466 results reinforce long-term growth narratives beyond Humira. 

What to Watch Next

Investors will now look to AbbVie’s earnings release scheduled for October 30 for additional financial context, including whether these clinical advancements align with expectations. Key areas to watch include potential guidance revisions and commentary on upcoming regulatory pathways, notably whether lutikizumab or ABBV‑466 will be positioned for accelerated review or submitted for approval.

In the meantime, these data enhancements reflect AbbVie’s deepening pipeline and diversification strategy, which remains a critical factor in assessing the company’s mid-to-long-term investment appeal.